AGGREGATED External reporting by Bloomberg. This page summarizes the publisher's feed entry; the full article is on www.bloomberg.com.
Novartis Abandons Heart Drug After Surprising Failure in Key Study
Novartis AG is largely abandoning an experimental drug analysts once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and cardiovascular deaths.